Outcome of patients with hepatitis C virus-related hepatocellular carcinoma occurring after interferon therapy
Komorizono, Y.; Sako, K.; Yamasaki, N.; Hiwaki, T.; Sakurai, K.; Shibatou, T.; Maeda, M.; Kohara, K.; Shigenobu, S.; Hasegawa, S.; Arima, T.; Oketani, M.; Ishibashi, K.; Arima, T.
Anticancer Research 22(6b): 3573-3578
2002
ISSN/ISBN: 0250-7005 PMID: 12552958 Document Number: 547189
To determine whether previous IFN therapy for chronic hepatitis C (HCV) infection influences the outcome of patients with hepatocellular carcinoma (HCC), 143 patients were enrolled in this study. Of 143 patients, 48 had received previous IFN therapy (IFN group) and the remaining 95 had not (untreated group). We estimated distant intrahepatic recurrence-free intervals and disease-specific survivals of the two groups by the Kaplan-Meier method and analyzed the difference by the log-rank test. Factors determining distant intrahepatic recurrence-free interval and disease-specific survival were studied by univariate and multivariate analysis using Cox proportional hazards regression model. The proportion of patients with single tumors was significantly higher in the IFN group (p = 0.026). The IFN group showed a significantly higher distant intrahepatic recurrence-free interval (p = 0.001) and disease-specific survival (p = 0.003). Moreover, multivariate analysis indicated that previous IFN therapy for chronic HCV infection was a significant independent factor for distant intrahepatic recurrence-free interval and disease-specific survival. These results indicate that previous IFN therapy reduces multicentric hepatocarcinogenesis of HCV-related HCC and improves the patients' survival.